Javascript must be enabled to continue!
Prognostic Value of CD40 in Adult Soft Tissue Sarcomas
View through CrossRef
Abstract
Purpose: The purpose is to evaluate the expression of CD40, a membrane protein predominantly expressed on B cells, dendritic cells, and macrophages, in a series of adult soft tissue sarcomas and to test its possible prognostic value.
Experimental Design: CD40 expression was studied by immunohistochemistry. Correlations with other baseline characteristics of patients and tumors were analyzed with χ2 test. The prognostic value was studied with univariable and multivariable analysis adjusted by age, sex, tumor size, grade, location, and distant metastases.
Results: Eighty-two patients, between January 1994 and May 2001, were analyzed. Membrane or cytoplasmic staining for CD40 protein was absent in 30% of the tumors but present in <10% of cells in 22 (27%), in 10% to 50% in 23 (28%), and in >50% of cells in 12 (15%) tumors. There was no correlation between CD40 expression and age, sex, size, grade, and location of the primary tumor and distant metastases. With 61 patients (74.4%) progressed and 31 (37.8%) dead, CD40 expression was a significant prognostic factor for disease-free and overall survival at univariable and multivariable analysis. Patients with tumors expressing CD40 in >50% of cells had a dramatically unfavorable prognosis with median disease-free and overall survival of 7 and 17 months, respectively, and hazard ratios of relapse and death as compared with patients with CD40-negative tumors of 2.89 (95% confidence interval: 1.26–6.60) and 6.92 (95% confidence interval: 2.18–22.0), respectively.
Conclusions: These data suggest that expression of CD40 protein in >50% of cells might indicate an unfavorable prognosis in adult soft tissue sarcomas.
American Association for Cancer Research (AACR)
Title: Prognostic Value of CD40 in Adult Soft Tissue Sarcomas
Description:
Abstract
Purpose: The purpose is to evaluate the expression of CD40, a membrane protein predominantly expressed on B cells, dendritic cells, and macrophages, in a series of adult soft tissue sarcomas and to test its possible prognostic value.
Experimental Design: CD40 expression was studied by immunohistochemistry.
Correlations with other baseline characteristics of patients and tumors were analyzed with χ2 test.
The prognostic value was studied with univariable and multivariable analysis adjusted by age, sex, tumor size, grade, location, and distant metastases.
Results: Eighty-two patients, between January 1994 and May 2001, were analyzed.
Membrane or cytoplasmic staining for CD40 protein was absent in 30% of the tumors but present in <10% of cells in 22 (27%), in 10% to 50% in 23 (28%), and in >50% of cells in 12 (15%) tumors.
There was no correlation between CD40 expression and age, sex, size, grade, and location of the primary tumor and distant metastases.
With 61 patients (74.
4%) progressed and 31 (37.
8%) dead, CD40 expression was a significant prognostic factor for disease-free and overall survival at univariable and multivariable analysis.
Patients with tumors expressing CD40 in >50% of cells had a dramatically unfavorable prognosis with median disease-free and overall survival of 7 and 17 months, respectively, and hazard ratios of relapse and death as compared with patients with CD40-negative tumors of 2.
89 (95% confidence interval: 1.
26–6.
60) and 6.
92 (95% confidence interval: 2.
18–22.
0), respectively.
Conclusions: These data suggest that expression of CD40 protein in >50% of cells might indicate an unfavorable prognosis in adult soft tissue sarcomas.
Related Results
Blood-Borne, but Not Endothelial CD40 Promotes Experimental Lung Metastasis.
Blood-Borne, but Not Endothelial CD40 Promotes Experimental Lung Metastasis.
Abstract
During experimental lung metastasis, procoagulant tumor cells adhere to the microvascular endothelium and activate coagulation, which leads to thrombin gene...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Cd40 Activation as Potential Tool in Malignant Neoplasms
Cd40 Activation as Potential Tool in Malignant Neoplasms
Background
CD40, a cell surface molecule, is expressed on B-cell malignancies and many different solid tumors. It is capable of mediating diverse biological phe...
Abstract 5049: Prediction of pharmacokinetics and receptor occupancy of a bispecific antibody against CD40 and PD-L1
Abstract 5049: Prediction of pharmacokinetics and receptor occupancy of a bispecific antibody against CD40 and PD-L1
Abstract
Background: Currently bispecific monoclonal antibodies gain traction in pharmacology as a way to simultaneously target different surface molecules on immune...
CD40 preferentially costimulates activation of CD4+ T lymphocytes.
CD40 preferentially costimulates activation of CD4+ T lymphocytes.
Abstract
CD40 is a membrane differentiation antigen constitutively expressed on B cells that induces B cell growth and Ig synthesis after ligation with anti-CD40 ...
CD40-CD40 ligand
CD40-CD40 ligand
Abstract
CD40 is a cell surface receptor that belongs to the tumor necrosis factor-R (TNF-R) family, and that was first identified and functionally characterized on ...
Agonistic CD40 Antibodies in Cancer Treatment
Agonistic CD40 Antibodies in Cancer Treatment
CD40 is expressed on a variety of antigen-presenting cells. Stimulation of CD40 results in inflammation by upregulation of other costimulatory molecules, increased antigen presenta...

